SUBSCRIBE
SUBSCRIBE
News   Drug Development

AVANIR Pharmaceuticals Announces Last Patient Enrolled In Neuropathic Pain Phase III Trial With Zenvia

November 15, 2006 | 
1 min read
SAN DIEGO--(BUSINESS WIRE)--AVANIR Pharmaceuticals (NASDAQ:AVNR) announced today that the Company has enrolled the targeted number of patients needed to assess the efficacy endpoint in its ongoing Zenvia Phase III painful diabetic neuropathy trial.
Clinical research Phase 3
MORE ON THIS TOPIC
Sorting garbage concept. Cropped photo of paper thash. Crumple paper falling to the recycling bin
Cancer
BMS scraps Orum’s targeted degrader after reviewing Phase 1 data
September 18, 2026
 · 
1 min read
 · 
Tristan Manalac
Bridging the gap connect the path to success together, teamwork or partnership, collaboration or cooperation for winning challenge, businessman connect jigsaw puzzle as the bridge to connect the gap.
Deals
Novo notches up to $1.4B pact with Orbis to develop oral macrocycle cardiometabolic drugs
September 17, 2026
 · 
2 min read
 · 
Michael Gibney
Stagflation, economic slow down or recession while inflation high up, GDP growth decrease causing by unemployment concept, fearful businessman riding fall down economic graph with inflation high up.
Cardiovascular disease
Longeveron’s shares crash as stem cell therapy flunks mid-stage cardio trial
September 17, 2026
 · 
2 min read
 · 
Tristan Manalac
Insights
When vision fades: Rethinking wet AMD and the durability gap
September 17, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker